Abstract
Background
Glucose-6-phosphate dehydrogenase (G6PD) is a housekeeping enzyme encoded on chromosome X. It is ubiquitously expressed in all body tissues and found in eukaryotes and prokaryotes alike. G6PD catalyses the rate-limiting first step in the pentose phosphate pathway, generating NADPH, an electron donor important in a variety of metabolic processes, including fatty and nucleic acid synthesis, nitric oxide production, and the regeneration of antioxidant glutathione. Deficiency of G6PD is the most common enzymopathy in man, with prevalence especially high in sub-Saharan Africa and southeast Asia. It is a trait that is thought to be both harmful and beneficial. While clinical penetrance is generally mild, G6PD deficiency can predispose to hemolytic anemia and neonatal jaundice, generally in the context of oxidant stressors generated by certain foods, medications, and infections. Counterbalancing these deleterious effects is evidence that suggests G6PD deficiency confers partial protection against malaria, and that such protection has conferred a selective advantage to G6PD-deficient individuals in malaria-endemic regions, as reflected in the close geographical correlation between the global distribution of G6PD deficiency and that of historical malaria endemicity. http://www.biomedcentral.com/1471-2350/ 15/93 Despite decades of research, however, our understanding of both beneficial and deleterious clinical phenotypes associated with G6PD deficiency remains incomplete. Association studies of severe malaria have disagreed over the strength and specificity of protection, especially with respect to gender, with past studies demonstrating protection for only males [1] , only females [2] , both [3, 4] , or neither [5] . Additionally, there is geographical heterogeneity in association testing results as well, with the only compelling evidence thus far coming from west Africa. Similarly, the precise determinants of the hemolytic response to oxidative stressors remain unknown. One especially important drug reaction is that involving the antimalarial primaquine [6, 7] . It is currently the only medication capable of radical cure of Plasmodium vivax infection and one of few drugs that acts against the Plasmodium falciparum gametocyte; it therefore has high value in eliminating reservoirs of infection and reducing transmission rates, tasks that are crucial to the success of any malaria elimination program [8] . While G6PD deficiency alleles are strongly associated with increased risk to primaquineinduced hemolysis, there exists significant unexplained variance in this association, especially for mosaic female heterozygotes [9] .
One challenging aspect to designing and interpreting clinical association studies lies in how G6PD deficiency is defined. While many genetic association studies at G6PD implicitly assume that one nonsynonymous coding variant has both full positive and negative predictive power for G6PD deficiency trait, this approach belies the considerable allelic heterogeneity present at the locus [4, 10, 11] . Indeed, G6PD deficiency is perhaps best understood as a family of heritable traits exhibiting widely varying prevalence, as well as differential biochemical and clinical penetrance, all factors which influence the power of an association test [4] . Additionally, it is possible that unrecognized genetic modifiers of G6PD activity have yet to be identified, and that these may play a role in determining an individual's G6PD deficiency status.
To inform our understanding of how genetic variation at G6PD impacts clinical outcomes, we sought to examine its more immediate relationship with molecular phenotypes. We took a comprehensive two-part approach, first resequencing the G6PD gene to validate known and discover novel variants, and then testing those polymorphisms for association with G6PD enzyme activity in Kenya.
Methods

Ethics statement
Ethics approval was granted by the Kenya Medical Research Institute (KEMRI) review board, and written informed consent was obtained from a parent or guardian prior to enrollment.
Sample collection
Capillary blood was drawn by heel prick from 2100 healthy infants (less than 6 months old) of predominantly Mijikenda ethnicity, recruited into an ongoing prospective birth cohort study run by KEMRI and the Wellcome Trust in Kilifi, Kenya (SCC1192: The genomic epidemiology of childhood diseases in Kilifi, Kenya). Samples were stored in EDTA at 4°C and processed for activity assays and DNA extraction within four days. Of note, serial assay measurements taken on the same samples remained consistent even up to 10-14 days from collection.
Enzyme activity assay
The assay used is a ten-fold scaled down version of the 'macro' assay given in Randox Laboratories G6PD kit (PD 410), using positive (PD 2618) and negative (PD 2617) controls where necessary. Ten microliters of whole blood was washed three times in 100 μl normal saline. Washed RBC were lysed by incubation with 25 μl of digitonin for 15 minutes at 4°C. Five microliters of the hemolysate was incubated with 300 μl of buffer (31.7 mM triethanolamine, 3.2 mM EDTA, pH = 7.6) and 10 μl NADP+ (0.34 mM) at 37°C for 5 minutes. Finally, five microliters of glucose-6-phosphate (0.58 mM) was added and spectrophotometry readings taken, with duplicate measurements taken for each sample. Catalytic rate was assessed by the formation of reaction product NADPH, which absorbs light at 340 nm. The change in absorbance at 340 nm was measured over a 3 minute time course using a plate spectrophotometer (Tecan). As we were unable to obtain hemoglobin or RBC concentrations for our samples to allow for reporting of activity in international units, activity is instead reported here in arbitrary units and was normalized to hemolysate hemoglobin content by recording absorbance at 540 nm:
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Sequencing and genotyping
Resequencing was performed as part of an exon sequencing project called ExoSeq at Wellcome Trust Sanger Institute (WTSI). A total of 288 individuals comprised our sample set, with 48 individuals each from Burkina Faso, Cameroon, Nigeria, Kenya, Vietnam, and Papua New Guinea. A total of 28 amplicons approximately 600-800 bp in length were designed via automated algorithm (i.e. in silico PCR), covering about two-thirds of the 15 kb G6PD gene, with full coverage of all exons, but a few gaps in noncoding sequence, specifically in introns 1 and 2. Capillary sequencing of the PCR products generated yielded chromatograms that were input into an automated SNP calling pipeline, which was supplemented with manual calls from examination of individual sequence traces. A http://www.biomedcentral.com/1471-2350/15/93 total of 72 SNPs, including forty-nine novel variants were identified. Genotyping was performed on the Sequenom® MASSarray® iPLEX® platform. A total of three multiplex genotyping reactions were designed, assaying a total of 68 SNPs. The SNPs input to the design software included those discovered during resequencing (N = 72), as well as nonsynonymous variants from the literature (N = 25), and several hundred variants within 1 Mb of G6PD extracted from dbSNP and Ensembl databases. Inclusion in the multiplex reactions was priority-weighted according to predicted functional consequence and estimated minor allele frequency criteria. Template DNA used for genotyping was genomic DNA amplified by primer extension pre-amplification [12] . Genotype calls were manually curated by examining cluster plots to identify ambiguous genotypes. Ancestral and derived alleles were inferred according to the Ensembl EPO pipeline.
Data curation and analysis
Enzyme activity data was filtered to keep only individuals with positive absorbance readings at both 340 and 540 nm, and checked for batch effects and extreme outliers. Genotype data was filtered using custom Perl and R scripts, along with PLINK [13] and snpMatrix [14] . Individuals exhibiting greater than 10% missing data or ambiguous gender (based on chromosome X genotypes) were excluded. SNPs were removed if they showed greater than 5% missing data, minor allele frequency < 1%, or extreme deviation from Hardy-Weinberg equilibrium (P < 10 −4 , Additional file 1). In total, 1828 of 2100 individuals and 30 out of 70 SNPs met these inclusion criteria (Additional file 2).
Statistical analyses were conducted in R [15] . Single marker tests of association for each derived allele were conducted via multiple linear regression. Covariates included sex, and in the controlled tests, c.202G>A genotype. Three different modes of inheritance are considered-in the additive model, male genotypes were coded 0 or 2, and females were 0, 1, or 2; in the dominant and recessive models, males were coded 0/1, and females were coded 0/1/1, or 0/0/1, respectively. Haplotypes were inferred using fastPHASE [16] under default settings with known male haplotypes used as a reference input to reduce search space and minimize phasing error rate in females (Additional file 3). All haplotypes with frequency > 1% (26 full-length, 13 partial) were tested for association; individuals were coded 0 or 1 based on absence/presence of the test haplotype, with females represented by one haplotype selected at random. Odds ratios (OR) for qualitative tests were calculated via logistic regression. Effect sizes (ES) are presented here with 95% confidence interval in brackets. Allele sharing distance was calculated using a Euclidean distance metric for each individual from both H+ and H-haplotypes. An individual is categorized as either H+ or H-if their distance metric falls into the lowest quintile of the respective empirical distribution. In linear modeling of the additive effect of allele sharing distance on enzyme activity, this categorization is coded as -1 (H-), 0 (neither), or +1 (H+).
Results
Variants studied
The variants studied here were ascertained using a combination of sources, including our own resequencing efforts, published accounts in the literature, and online variation databases. Resequencing was carried out as part of an ongoing laboratory effort to catalogue global genetic variation at the G6PD locus (manuscript in preparation). A total of 15 kb at the G6PD locus was sequenced in a worldwide panel comprised of 288 African and Asian individuals, including 48 from Kenya. This work identified a total of 72 SNPs, including 49 novel variants. Published accounts in the literature yielded an additional 25 nonsporadic, nonsynonymous variants associated with G6PD deficiency in Africa and Asia, including 5 that have been identified in sub-Saharan Africa [10] : the c.202G>A, c.376A>G, c.542A>T, c.680G>T, and c.968T>C polymorphisms (number refers to cDNA coordinate). Finally, several hundred polymorphisms (mostly noncoding SNPs) within 1 Mb of G6PD were also identified in dbSNP and Ensembl to supplement our list.
This list of several hundred SNPs was then priorityweighted according to predicted functional consequence (e.g. nonsynonymous, splice site, etc.), estimated allele frequency, and proximity to G6PD in order to decide which would be prioritized for inclusion in genotyping assays. A total of 68, including all five nonsynonymous African variants, were typed in the current study using the Sequenom® MASSarray® iPLEX® platform. Of the SNPs typed, 30 met final study inclusion criteria, which included having derived allele frequency (DAF) greater than 0.01 and less than 5% missing data. It should be noted that most excluded SNPs failed based on DAF criteria, as many were private to west Africa or Asia. This included the c.542A>T, c.680G>T, and c.968T>C variants, which were monomorphic (DAF = 0%) in Kenya. The only two nonsynonymous variants at the locus that were found to be polymorphic in Kenya were c.202G>A and c.376A>G, exhibiting DAF of 17% and 40%, respectively. All SNPs included in the association study are shown in Additional file 2. , additive model), a nonsynonymous coding SNP (rs1050828; Val68Met) known to be associated with G6PD enzyme deficiency in many parts of sub-Saharan Africa. The effect size for the 202A allele corresponds to a roughly 40% reduction in enzyme activity for heterozygotes, and 80% for hemizygotes and homozygotes, consistent with previous estimates [17] [18] [19] . Since linkage disequilibrium with c.202G>A was highly correlated with signal strength at all other sites, we repeated the association testing including c.202G>A genotype as a covariate. In these controlled tests, we found strong evidence of a causal role for 202A, as all other association signals drop off by many orders of magnitude ( Figure 2 , Additional file 5), though twelve SNPs still retained significance at P < 10 −3 , suggesting a role independent of c.202G>A, with allelic ES estimates for each SNP corresponding to 3-4% changes in enzyme activity.
Modifiers of G6PD activity that are independent of c.202G>A
As these twelve SNPs exhibited similar P values and effect size magnitudes (Figure 2 , Additional file 5), and were all common variants (DAF > 0.25) at a locus exhibiting a strong pattern of linkage disequilibrium (Additional file 6), we considered the parsimonious hypothesis that they were all related signals. Upon examination of all haplotypes across these twelve sites, it was found that the two most frequent haplotypes (H+ = 19%; H-= 22%) were: (a) exactly opposite in allele identity (Figure 3c Figure 3c ). In association testing of all full-length and twelve-site haplotypes, it was observed that the haplotypes most suggestive of association at P < 0.025 similarly exhibited differential ES direction and resembled either H+ or H-in sequence identity (Figure 3a and b, Additional file 7) . Additionally, the extent of allele sharing with either the H+ or H-haplotype was correlated with enzyme activity independent of c.202G>A (P = 2.3 × 10 −6 , additive linear model, Additional file 8). Lastly, it was noted that SNPs tagging http://www.biomedcentral.com/1471-2350/15/93 the H+ (rs2230037) and H-(c.376A>G) haplotypes, in concert with c.202G>A, were sufficient to describe a minimal adequate genetic model of G6PD activity that could explain 41% of variance in enzyme activity (Table 1) .
While the association of c.376A>G with a modest reduction in enzyme activity (approximately 10-20% in male hemizygotes) has been reported previously [20, 21] , and this has been generally thought to be the result of changes to protein structure leading to enzyme instability, it should be emphasized that neither the controlled association scan nor subsequent haplotype testing was suggestive of a uniquely causal role for c.376A>G. Indeed, what our work suggests instead is the possibility that this nonsynonymous variant is merely a marker, as it is only one of nine SNPs tagging the H-haplotype and one of twelve overall that exhibits modest effects independent of c.202G>A.
Both c.202G>A and c.376A>G contribute to risk of G6PD deficiency state
We also examined qualitative G6PD activity status, using the intermodal trough of the bimodal activity distribution in males as an ad hoc cutoff to distinguish normal from deficient ( Figure 4A , Additional file 9). Overall, using the clearer distribution profile in males, we estimate that the prevalence of G6PD deficiency in our cohort is 18%, and that 202A accounts for 85% of this figure, which suggests that there may be rare functional variants we were underpowered to discover, consistent with observations elsewhere in east Africa [19] . A total of 162 males and 97 females could be categorized as deficient, including 93% of both 202A hemizygote males and 202AA homozygote females, but notably also 20% of 202AG heterozygotes.
While it is known that the distribution of enzyme activity in 202AG female heterozygotes is broad, with some individuals exhibiting an effectively deficient biochemical phenotype, little is known about the genetic factors that might contribute to this risk. We tested the possibility that our H-tag SNP, c.376A>G, might reduce enzyme activity sufficiently to augment risk of phenotypic G6PD deficiency state in such individuals. The 202A allele is known to obligately lie on a 376G background in African populations to form the ' A-' haplotype [17, 22, 23] , and thus 202AG individuals can be either 376GA or 376GG. We found that among 202AG heterozygotes, those that were 376GG exhibited not only reduced enzyme activity http://www.biomedcentral.com/1471-2350/15/93 as compared to 376GA (ES = -0.06 [-0.10 --0.03], P = 0.0009, Figure 4b ), a trend consistent with that observed earlier in 202 wild-type individuals, but were also notably at increased risk for deficiency state (OR = 2.11 [1.12 -3 .84], P = 0.014). This latter finding has not been previously reported, and represents the first demonstration of a genetic modifier that influences risk to deficiency state in individuals heterozygous for the A-form of G6PD deficiency.
Discussion
The work presented here represents the first fine-mapping association study of enzyme activity at the G6PD locus, and provides new insights into the genetic basis for quantitative and qualitative variation in this clinicallyimportant molecular phenotype. We found that the largest proportion of variance in G6PD activity could be explained by a single polymorphism, c.202G>A, a coding variant thought to be a target of recent positive selection [24, 25] , but one that has yielded conflicting results in previous association studies of severe malaria. In addition, we found that certain common variants at the locus modulate G6PD activity independent of c.202G>A, and identify among these a role for c.376A>G as a genetic modifier which augments by two-fold the risk of G6PD deficiency state in 202AG heterozygote females. Taken together, these results suggest that future clinical association studies in Africa should consider the effects of both of these variants in order to arrive at a more accurate genetic definition of phenotypic G6PD deficiency state.
Our study is the first to systematically consider the possibility that other SNPs, even those found several hundred kilobases away from G6PD, might be associated with G6PD deficiency, and that c.202G>A might only be indirectly associated with deficiency, a finding which could explain discrepancies in previous association studies. Although the number of SNPs surveyed here is relatively small and does not include rare variants, we did not observe any SNPs more strongly associated with G6PD deficiency in Kenya than the c.202G>A variant, strongly suggestive of a causal role. Additionally, while all known functional variants in sub-Saharan Africa were genotyped as part of our study, only c.202G>A was found to be polymorphic in Kenya (DAF = 17%). This allelic homogeneity contrasts with the situation in some areas of west Africa [4] , and suggests that given a similar allele frequency and biochemical penetrance, clinical association studies of malaria in each region should be equivalently powered if indeed the G6PD deficiency trait is directly responsible for protection. The strongest evidence implicating G6PD deficiency in malaria protection would ideally be consistent with an additive genetic model, with hemizygous males and homozygous females exhibiting similar clinical phenotypes, and heterozygous females displaying intermediate phenotypes.
Our work also demonstrates the power of a haplotypebased approach in resolving multiple correlated association signals in a region. Though we found two haplotype motifs that were common and of significant effect independent of c.202G>A, we were unable to further localize the signal, even when examining all possible two-and three-locus haplotypes (data not shown), suggesting that these haplotypes are merely markers for the true causal variants. Interestingly, among the twelve variants of significant effect independent of c.202G>A were c.376A>G, a nonsynonymous coding variant, as well as rs915942 and rs111827785, predicted 5' UTR splice-site variants within RPL10 (a large-subunit ribosomal gene) and G6PD, respectively. While we can only speculate as to the precise nature of the structurefunction relationship mediating these effects, the biology of the locus makes for interesting possibilities for interaction between c.202G>A and the H+/H-variants, including the possibility of cell-cell interactions synergistically impacting enzyme activity distribution in 202AG mosaic females.
At one level, the work presented here reveals how common, standing genetic variation superimposed on a Mendelian trait can significantly impact expression of that trait. More important, however, is how this finding might translate into a better understanding of how G6PD deficiency is linked to key clinical phenomena. Specifically, it will be worth considering whether two site genetic testing is more predictive of clinical outcome than single SNP testing in women heterozygous for the common A-form of G6PD deficiency in Africa. For example, in considering a public health intervention such as mass primaquine administration as part of a malaria elimination campaign, two-site testing might help to identify the subset of A-heterozygotes more likely to be susceptible to acute hemolytic anemia. Lastly, at a more general level, our work highlights the importance of measuring intermediate molecular phenotypes that can bridge the gulf between variance at the genetic level and variance in clinical phenotypes. This is especially important for association studies of G6PD deficiency given its considerable allelic heterogeneity, varying biochemical penetrance, and long history of inconsistent findings.
Conclusions
We have surveyed genetic variation at the G6PD locus in Kenya via resequencing, and conducted a fine-mapping association study of erythrocyte G6PD activity. We find that while the c.202G>A polymorphism accounts for most of the variance in enzyme activity seen in this population, several other common polymorphisms are also relevant, http://www.biomedcentral.com/1471-2350/15/93 specifically noting that c.376A>G acts as a genetic modifier which increases by two-fold the risk of deficiency state in 202AG heterozygotes. Our results suggest that multiple alleles at the G6PD locus play a role in determining G6PD deficiency state and therefore merit consideration in genetic association studies of clinical phenotypes such as severe malaria or drug sensitivity.
